The first regenerative
therapy for
ischemic stroke.
The brain tries to repair itself, but it cannot do it alone.
B recover is a first-in-class regenerative therapy for ischemic stroke survivors.
A new possibility when no therapeutic options remain.
The problem
Ischemic stroke devastates everything in its path.
Ischemic stroke is the second leading cause of death and the leading cause of disability worldwide.
When it happens, time is brain. But for millions of people, the real challenge begins right after.
- Adults who fall outside the current therapeutic window.
- Children for whom diagnosis arrives too late.
- Newborns for whom no approved treatment exists.
Today, once brain damage has occurred, options remain very limited.
The solution
We help the brain to repair itself.
When stroke occurs the brain tries to repair itself, but it cannot do it alone. B recover is designed to promote the brain's endogenous repair mechanisms.
Where damage has destroyed tissue, we offer fertile ground for life to take hold again.
An advanced biomaterial that replaces the lost extracellular matrix, promotes tissue regeneration and functional recovery.
The result of years of biomaterials science research now driven by Ombú, closer to patients.
For the first time, a regenerative therapy that targets irreversible brain tissue loss after ischemic stroke, opening an entirely new therapeutic category.
WHO IT EXISTS FOR
Designed for every ischemic stroke survivor.
Newborns
An orphan condition for which no specific approved treatments currently exist.
Children
Patients who receive a late diagnosis and lack specific therapeutic alternatives.
Adults
People who have fallen outside the current therapeutic window and need new recovery options.
Take part
We want to build
B recover with you
Innovation thrives through collaboration.
We are developing B recover alongside those who will be part of its future: investors, industry partners, healthcare professionals, patients, and families.
Are you an investor?
We are advancing B recover through preclinical studies toward First-in-Human, with a clear B2B licensing model.
We are looking for individuals and organizations who want to join us on the path toward a new therapeutic category for stroke.
Request investor information
Are you a potential licensee
Ombú is advancing a first-in-class regenerative asset toward a value-inflection point for partnering.
We are looking for the right industry partner to lead its next stage of development and bring this innovation to patients.
Request licensee information
Do you work in a clinical setting?
The insights of healthcare professionals who care for patients every day are essential to developing solutions that are both meaningful and clinically relevant.
We would love to learn from your perspective and explore how B-Recover can better meet the realities and needs of everyday clinical practice.
Share your clinical experience
Are you a patient or family member?
The voices of patients and families are essential to developing therapies that truly make a difference.
We would be humbled to hear your story and learn from your experience.
Share your experience
Ombú
From the laboratory to the clinic.
From bench to people.
We are currently advancing B recover through preclinical development with the goal of entering first-in-human clinical trials. Every milestone brings us closer to offering a regenerative approach where no treatment currently exists.
B recover is being developed by Ombú, a deep-tech company transforming science into therapies that create new possibilities for patients.
